1 day Ago By Defense World Staff
Franklin Resources Inc. raised its position in shares of Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX – Free Report ) by 299.
6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 75,779 shares of the company’s stock after acquiring an additional 56,816 shares during the period. Franklin Resources Inc.
’s holdings in Recursion Pharmaceuticals were worth $512,000 at the end of the most recent reporting period. A number of other large investors also recently modified their holdings of the company. Stifel Financial Corp raised its stake in shares of Recursion Pharmaceuticals by 48.
8% in the 3rd quarter. Stifel Financial Corp now owns 161,978 shares of the company’s stock valued at $1,067,000 after acquiring an additional 53,103 shares during the period. Wellington Management Group LLP purchased a new stake in shares of Recursion Pharmaceuticals in the third quarter worth about $692,000.
Barclays PLC grew its stake in shares of Recursion Pharmaceuticals by 53.9% in the third quarter. Barclays PLC now owns 697,432 shares of the company’s stock valued at $4,596,000 after buying an additional 244,278 shares in the last quarter.
Geode Capital Management LLC lifted its position in Recursion Pharmaceuticals by 13.7% during the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after acquiring an additional 656,003 shares in the last quarter.
Finally, Sanctuary Advisors LLC purchased a new position in Recursion Pharmaceuticals in the 3rd quarter worth approximately $89,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes RXRX has been the subject of a number of analyst reports. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $7.
00 to $6.00 and set a “market perform” rating for the company in a report on Friday, February 28th. Morgan Stanley reduced their target price on Recursion Pharmaceuticals from $10.
00 to $8.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. Needham & Company LLC reissued a “buy” rating and set a $11.
00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Finally, KeyCorp decreased their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.
00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.
com, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus price target of $8.20. Recursion Pharmaceuticals Price Performance Shares of NASDAQ:RXRX opened at $5.
50 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.
79 and a 52 week high of $12.36. The firm’s 50 day moving average is $6.
66 and its two-hundred day moving average is $6.80. The company has a current ratio of 4.
35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.
The firm has a market capitalization of $2.21 billion, a P/E ratio of -3.59 and a beta of 1.
00. Recursion Pharmaceuticals ( NASDAQ:RXRX – Get Free Report ) last announced its earnings results on Friday, February 28th. The company reported ($0.
53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17).
Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%.
The firm had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million.
Recursion Pharmaceuticals’s revenue for the quarter was down 57.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.
42) EPS. Analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.
57 earnings per share for the current year. About Recursion Pharmaceuticals ( Free Report ) Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also Five stocks we like better than Recursion Pharmaceuticals How to trade penny stocks: A step-by-step guide Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Low PE Growth Stocks: Unlocking Investment Opportunities Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar What Makes a Stock a Good Dividend Stock? Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX – Free Report ). Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
